Arvinas (NASDAQ:ARVN) Stock Rating Upgraded by Wall Street Zen

Arvinas (NASDAQ:ARVN) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

A number of other analysts have also recently issued reports on ARVN. Stephens restated an “overweight” rating and set a $18.00 price objective on shares of Arvinas in a research report on Wednesday, June 3rd. Weiss Ratings cut Arvinas from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 30th. BTIG Research reiterated a “buy” rating and set a $18.00 price target on shares of Arvinas in a research note on Tuesday, August 4th. Wells Fargo & Company reissued an “equal weight” rating and issued a $11.00 price target (down from $15.00) on shares of Arvinas in a report on Tuesday, August 4th. Finally, Wedbush increased their price objective on shares of Arvinas from $11.00 to $12.00 and gave the company a “neutral” rating in a research note on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $14.90.

Arvinas Price Performance

Shares of ARVN opened at $8.75 on Friday. Arvinas has a 12-month low of $6.09 and a 12-month high of $14.51. The firm has a market capitalization of $564.55 million, a price-to-earnings ratio of 87.51 and a beta of 1.71. The stock’s 50-day moving average price is $8.05 and its 200 day moving average price is $10.23.

Arvinas (NASDAQ:ARVN) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of ($0.37) by $2.95. Arvinas had a return on equity of 1.91% and a net margin of 2.94%.The firm had revenue of $249.70 million during the quarter, compared to analysts’ expectations of $60.71 million. During the same quarter in the prior year, the firm posted ($0.84) EPS. The company’s revenue for the quarter was up 1014.7% on a year-over-year basis. Equities research analysts expect that Arvinas will post -1.15 EPS for the current year.

Insider Activity

In related news, CFO Andrew Saik sold 5,696 shares of the stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $8.16, for a total transaction of $46,479.36. Following the completion of the sale, the chief financial officer owned 187,432 shares in the company, valued at $1,529,445.12. This trade represents a 2.95% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 7.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On Arvinas

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ARVN. BlackRock Inc. bought a new stake in Arvinas during the 2nd quarter worth approximately $63,232,000. Armistice Capital LLC raised its position in Arvinas by 50.0% in the 4th quarter. Armistice Capital LLC now owns 1,800,000 shares of the company’s stock valued at $21,348,000 after purchasing an additional 600,000 shares during the last quarter. TCG Crossover Management LLC acquired a new position in Arvinas in the third quarter worth $13,780,000. Qube Research & Technologies Ltd grew its holdings in shares of Arvinas by 154.8% during the third quarter. Qube Research & Technologies Ltd now owns 1,486,864 shares of the company’s stock worth $12,668,000 after purchasing an additional 903,337 shares during the last quarter. Finally, Millennium Management LLC grew its holdings in shares of Arvinas by 208.4% during the first quarter. Millennium Management LLC now owns 1,310,326 shares of the company’s stock worth $9,198,000 after purchasing an additional 885,483 shares during the last quarter. 95.19% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Arvinas

Here are the key news stories impacting Arvinas this week:

• Positive Sentiment: Zacks upgraded Arvinas to “Strong Buy.” The firm’s Zacks Rank #1 reflects improving expectations for the company’s earnings outlook and could support further buying interest. Arvinas Upgraded to Strong Buy
• Positive Sentiment: Arvinas reported a major quarterly earnings and revenue beat. Adjusted earnings were $2.58 per share versus the consensus estimate of a $0.37 loss, while revenue reached $249.7 million compared with expectations of $60.7 million. The sharp year-over-year revenue increase provides a fundamental reason for the recent rise in the shares. Arvinas Trading Higher on Strong Earnings
• Positive Sentiment: HC Wainwright raised several longer-term EPS estimates. The firm improved its forecasts for fiscal 2026 through 2029 and moved its fiscal 2030 outlook to a profit of $0.07 per share from a projected loss, suggesting better long-term operating prospects.
• Neutral Sentiment: Analyst opinions remain divided. BTIG maintained a Buy rating, while Wells Fargo lowered its rating to Equal Weight, limiting the impact of the bullish Zacks call. Arvinas Earns Buy Rating from BTIG Arvinas Rating Lowered to Equal Weight
• Negative Sentiment: HC Wainwright cut its near-term earnings forecasts. Q3 2026 EPS was reduced to a loss of $1.20 from $1.02, and Q4 EPS to a loss of $1.19 from $1.02. The revisions reinforce expectations for continued losses and may weigh on the stock.
• Negative Sentiment: A recent analyst downgrade pressured the shares. The downgrade adds caution after the earnings-driven advance, particularly given Arvinas’ projected full-year loss and its position below the 200-day moving average. Arvinas Shares Down on Analyst Downgrade

Arvinas Company Profile

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.